These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 25996253)

  • 1. Survey of coagulation factor concentrates tender and procurement procedures in 38 European Countries.
    O'Mahony B; Noone D; Prihodova L
    Haemophilia; 2015 Jul; 21(4):436-43. PubMed ID: 25996253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant clotting factors in the treatment of hemophilia.
    Lee C
    Thromb Haemost; 1999 Aug; 82(2):516-24. PubMed ID: 10605745
    [No Abstract]   [Full Text] [Related]  

  • 3. The challenge arising from the cost of haemophilia care: an audit of haemophilia treatment at Auckland Hospital.
    Harper P; Brasser M; Moore L; Teague L; Pitcher L; Ockelford P
    N Z Med J; 2003 Aug; 116(1180):U561. PubMed ID: 14581983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Participation in research: the economic advantages in a haemophilia research population.
    Wasserman J; Ullman M; Cantini M; Moynihan K; Hoots WK
    Haemophilia; 2000 Sep; 6(5):571-4. PubMed ID: 11012704
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost-of-illness study of severe haemophilia A and B in five French haemophilia treatment centres.
    Nerich V; Tissot E; Faradji A; Demesmay K; Bertrand MA; Lorenzini JL; Briquel ME; Pouzol P; Woronoff-Lemsi MC
    Pharm World Sci; 2008 Jun; 30(3):287-92. PubMed ID: 18085428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Haemophilia care in Europe: a survey of 19 countries.
    O'Mahony B; Noone D; Giangrande PL; Prihodova L
    Haemophilia; 2011 Jan; 17(1):35-40. PubMed ID: 20722746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Will recent innovations in therapy save perceived deficiencies in self-sufficiency policies.
    Limentani SA
    Blood Coagul Fibrinolysis; 1994 Dec; 5 Suppl 4():S81-4. PubMed ID: 7795145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current issues in prophylactic therapy for persons with hemophilia.
    Dunn AL; Abshire TC
    Acta Haematol; 2006; 115(3-4):162-71. PubMed ID: 16549891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidemiological survey of haemophiliacs with inhibitors in France: orthopaedic status, quality of life and cost--the 'Statut Orthopédique des Patients Hémophiles' avec Inhibiteur study.
    Stieltjes N; Torchet MF; Misrahi L; Roussel-Robert V; Lambert T; Guérois C; Bertrand MA; Briquel ME; Borel-Derlon A; Dirat G
    Blood Coagul Fibrinolysis; 2009 Jan; 20(1):4-11. PubMed ID: 20527720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of the new generation recombinant factor concentrates.
    Schlesinger KW; Ragni MV
    Expert Opin Drug Saf; 2002 Sep; 1(3):213-23. PubMed ID: 12904137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changing paradigm of prophylaxis with longer acting factor concentrates.
    Carcao M
    Haemophilia; 2014 May; 20 Suppl 4():99-105. PubMed ID: 24762284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors.
    Astermark J; Morado M; Rocino A; van den Berg HM; von Depka M; Gringeri A; Mantovani L; Garrido RP; Schiavoni M; Villar A; Windyga J;
    Haemophilia; 2006 Jul; 12(4):363-71. PubMed ID: 16834735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Describing the quality of life of boys with haemophilia in China: Results of a multicentre study using the CHO-KLAT.
    Tang L; Xu W; Li CG; Hou F; Feng XQ; Wang H; Li XJ; Li WL; Liu JP; Sun LR; Wang SH; Jin J; Fang Q; Luke KH; Poon MC; Blanchette VS; Usuba K; Young NL; Wu R
    Haemophilia; 2018 Jan; 24(1):113-119. PubMed ID: 28922525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylaxis in children with hemophilia: is it the optimal treatment?
    Lusher JM
    Thromb Haemost; 1997 Jul; 78(1):726-9. PubMed ID: 9198246
    [No Abstract]   [Full Text] [Related]  

  • 15. [Quality of life of young patients with haemophilia in Europe].
    Bullinger M; Gringeri A; von Mackensen S
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jun; 51(6):637-45. PubMed ID: 18481032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of coagulation factor replacement with and without prednisolone in the treatment of haematuria in haemophilia and Christmas disease.
    Rizza CR; Kernoff PB; Matthews JM; McLennan CR; Rainsford SG
    Thromb Haemost; 1977 Feb; 37(1):86-90. PubMed ID: 320712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Haemophilia patients' unmet needs and their expectations of the new extended half-life factor concentrates.
    von Mackensen S; Kalnins W; Krucker J; Weiss J; Miesbach W; Albisetti M; Pabinger I; Oldenburg J
    Haemophilia; 2017 Jul; 23(4):566-574. PubMed ID: 28370896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current status of hemophilia patients and recombinant coagulation factor concentrates in Japan.
    Fukutake K
    Semin Thromb Hemost; 2000; 26(1):29-32. PubMed ID: 10805278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching haemophilia products and inhibitor risk: a United States' perspective.
    Nance D; Rodgers GM
    Eur J Haematol; 2015 Apr; 94(4):283. PubMed ID: 25800968
    [No Abstract]   [Full Text] [Related]  

  • 20. Real-life experience in switching to new extended half-life products at European haemophilia centres.
    Peyvandi F; Garagiola I; Boscarino M; Ryan A; Hermans C; Makris M
    Haemophilia; 2019 Nov; 25(6):946-952. PubMed ID: 31418967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.